Amphotericin B
- Generic Name
- Amphotericin B
- Brand Names
- Abelcet, Ambisome, Amphotec, Fungizone
- Drug Type
- Small Molecule
- Chemical Formula
- C47H73NO17
- CAS Number
- 1397-89-3
- Unique Ingredient Identifier
- 7XU7A7DROE
- Background
Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL in vitro. While Candida albicans is generally quite susceptible to amphotericin B, non-albicans species may be less susceptible. Pseudallescheria boydii and Fusarium sp. are often resistant to amphotericin B. The antibiotic is without effect on bacteria, rickettsiae, and viruses.
- Indication
Used to treat potentially life threatening fungal infections.
- Associated Conditions
- Coccidioidomycosis, Fungal Infections, Histoplasmosis, Invasive Aspergillosis, Invasive Fungal Infections, Leishmaniasis, Meningitis, Cryptococcal, Meningitis, Fungal, Mucocutaneous Leishmaniasis, Mycotic endophthalmitis, Penicillium marneffei infection, Visceral Leishmaniasis, Candidal cystitis, Disseminated Cryptococcosis, Fungal osteoarticular infections, Ocular aspergillosis, Refractory aspergillosis, Severe Coccidioidomycosis, Severe Cryptococcosis, Severe Fungal infection caused by Basidiobolus spp., Severe Fungal infection caused by Conidiobolus spp., Severe Fungal infection caused by sporotrichosis spp., Severe Histoplasmosis, Severe Mucocutaneous leishmaniasis, Severe North American blastomycosis, Severe Systemic candidiasis
Pilot Study of High Dose Liposomal Amphotericin B Efficacy in Initial Zygomycosis Treatment
- First Posted Date
- 2007-05-01
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 40
- Registration Number
- NCT00467883
- Locations
- 🇫🇷
Hôpital Necker - Service des Maladies Infectieuses et Tropicales, Paris, France
🇫🇷Necker Hospital, Paris, France
Intermittent Liposomal Amphotericin B Primary Prophylaxis
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2007-03-23
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- Bayside Health
- Target Recruit Count
- 60
- Registration Number
- NCT00451711
- Locations
- 🇦🇺
The Alfred Hosptial, Melbourne, Victoria, Australia
🇦🇺Box Hill Hospital, Eastern Health, Melbourne, Victoria, Australia
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study
- Conditions
- Mucormycosis
- Interventions
- First Posted Date
- 2007-01-09
- Last Posted Date
- 2023-10-16
- Target Recruit Count
- 20
- Registration Number
- NCT00419770
- Locations
- 🇺🇸
UCSF, San Francisco, California, United States
🇺🇸Duke University, Durham, North Carolina, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections
- Conditions
- Acute Myelogenous LeukemiaMyelodysplastic Syndrome
- Interventions
- First Posted Date
- 2007-01-05
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT00418951
- Locations
- 🇺🇸
The University of Texas M D Anderson Cancer Center, Houston, Texas, United States
PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia
- Conditions
- Leukemia
- First Posted Date
- 2006-08-10
- Last Posted Date
- 2015-07-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT00362544
- Locations
- 🇫🇷
Gilead Sciences, Paris, France
COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis
- Conditions
- Invasive Aspergillosis
- First Posted Date
- 2006-06-07
- Last Posted Date
- 2015-07-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT00334412
- Locations
- 🇫🇷
Gilead Sciences, Paris, France
PROPHESSOR: AmBisome in Antifungal Primary Prophylaxis Treatment of High Risk Patients Undergoing Allogeneic Stem Cell Transplantation
- First Posted Date
- 2006-05-16
- Last Posted Date
- 2010-02-12
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 34
- Registration Number
- NCT00326157
- Locations
- 🇮🇹
Gilead Sciences, Milan, Italy
Abelcet Radiotagging Protocol: Inhaled Lipid Complex Abelcet® in Lung Transplant Recipients
- Conditions
- Lung TransplantationLung Diseases
- First Posted Date
- 2005-10-10
- Last Posted Date
- 2008-12-17
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 12
- Registration Number
- NCT00235651
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis
- Conditions
- Visceral Leishmaniasis
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2014-10-03
- Lead Sponsor
- PATH
- Target Recruit Count
- 667
- Registration Number
- NCT00216346
- Locations
- 🇮🇳
Rajendra Memorial Research Institute of Medical Sciences (ICMR), Agam Kuan, Patna, Bihar, India
🇮🇳Kalazar Research Centre, Patna, Bihar, India
🇮🇳Kala-azar Medical Research Centre, Rambagh Road Muzaffarpur, Bihar, India
Comparison of 2 Antifungal Treatment (Empirical Versus Pre-Empirical) Strategies in Prolonged Neutropenia
- Conditions
- Malignant HemopathyDuration of Neutropenia Following Chemotherapy > 10 Days
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2006-09-21
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 300
- Registration Number
- NCT00190463
- Locations
- 🇫🇷
Chu Henri Mondor, Paris, Ile de France, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.